Xingqi Eye Pharma's SQ-25012 Injection Cleared for Thyroid Eye Disease Trial
On September 15, 2026, Xingqi Eye Pharma announced that it had received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SQ-25012 injection, agreeing to the conduct of a clinical trial of the drug for the proposed treatment of thyroid eye disease.
SQ-25012 injection is a recombinant humanized IgG1 trispecific antibody and is a Class 1 innovative therapeutic biologic.
The company has completed pharmaceutical and nonclinical pharmacology and toxicology studies of the drug.
As of the date of the announcement, no product of the same type has been approved for marketing.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a long term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 40
- Confidence
- 70%
- Horizon
- Long term
Biotechnology
- Direction
- positive
- Intensity
- 35
- Confidence
- 65%
- Horizon
- Long term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.